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Abstract 
Polyester-based nanoparticulates (NPs) are ideal nanocarriers for intracellular delivery of 
anticancer drugs because of their biocompatibility. However, an on-going challenge is the controlled 
and enhanced release of encapsulated therapeutics in response to unique changes that occur within 
cancer cells. Herein, we report the versatility of dual responses to enzymatic and oxidative reactions 
found in cancer cells toward the development of polyester-NPs as effective tumor-targeting 
intracellular nanocarriers. A facile nanoprecipitation method allows for the preparation of hydrophobic 
cores composed of novel polyester designed with esterase-responsive ester groups and oxidation-
responsive sulfide linkages on their backbones, physically stabilized with poly(ethylene glycol)-based 
polymeric shells. The formed core/shell-type NPs with a diameter of 120 nm exhibit excellent colloidal 
stability in physiological conditions and in the presence of serum proteins. When exposed to esterase 
and hydrogen peroxide, NP integrity is disrupted, leading to the enhanced release of encapsulated 
doxorubicin, confirmed by dynamic light scattering and spectroscopic analysis. Combined results from 
epifluorescence microscopy, confocal laser scanning microscopy, flow cytometry, and cell viability 
demonstrate that doxorubicin-loaded NPs reveals rapid penetration and enhanced intracellular release 
of doxorubicin, thus inhibiting tumor progression. Importantly, the cellular uptake of doxorubicin-
loaded core/shell NPs primarily via caveolae-dependent mechanism promotes their use in targeting a 
broad spectrum of cancers. 
Keywords: ROS, esterase, dual stimuli-responsive degradation, polyester nanoparticles, controlled 
release, enhanced penetration, drug delivery 
 
Introduction 
Cancer is one of the leading causes of death worldwide, and tremendous resources have been 
devoted to develop anticancer therapies over the past few decades. Small molecule anticancer drugs, 
while having been used as effective chemotherapeutics, typically are not selective to cancer cells, and 
thus cause severe side effects. Further, high doses of drugs must be administered to overcome issues 
with solubility, metabolic reactivity, and/or poor efficacy due to their elimination by kidney filtration 
(or renal clearance) during blood circulation.[1-3] Recent efforts have shifted toward the development 
of methods that allow for the controlled delivery and release of small molecule anticancer drugs to 
improve their efficacy. Polymer-based drug delivery systems (PDDS),[4-7] particularly hydrophobic 
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biocompatibility as well as ability to encapsulate therapeutic agents and deliver them to tumor tissues. 
Upon intravenous injection, well-designed PDDS with excellent colloidal stability have prolonged 
blood circulation; thus offering improved pharmacokinetics and biodistribution to tumors via enhanced 
permeability and retention (EPR).[11-13] Followed by their endocytosis into cancer cells, drug-loaded 
PDDS are subjected to the release of encapsulated drugs inside cells, thus minimizing side effects and 
maximizing therapeutic efficacy common to small molecule anticancer drugs. However, 
conventionally-designed PDDS remain a challenge to the controlled release of encapsulated drugs in 
the targeted cells. 
Stimuli-responsive degradation (SRD) has been explored as a promising platform in the design of 
smart PDDS. SRD involves the incorporation of dynamic covalent linkages into the design of PDDS; 
when needed, the response of these linkages to external stimuli changes their chemical and physical 
properties. In such, SRD-exhibiting PDDS, which are stable under physiological conditions, can be 
dissociated in a controlled fashion as cellular components are provided appropriate stimuli, thus 
enabling biodegradation.[14-18] Acidic pH, glutathione, reactive oxygen species (ROS), and 
enzymatic activities are typical examples of endogenous stimuli, while light and temperature are 
exogenous stimuli.[19-21] The response to these stimuli has led to more precise control over the 
dissociation or disintegration of smart PDDS.[22-24] In particular, enzyme-responsive systems are 
especially promising in that enzymes are great catalysts with high selectivity towards specific 
substrates. Overexpressed disease-associated enzymes such as esterase are effective cellular 
triggers.[25, 26] With growing interest in enzyme-responsive platform, numerous PDDS have been 
designed with specific peptide linkages[27-32] or backbone ester or amide linkages.[33-37] In addition 
to esterase, ROS such as hydrogen peroxide, superoxide, hydroxyl radical, and hypochlorite is found at 
elevated concentrations in cancer cells compared to healthy cells.[38, 39] Most ROS-responsive 
systems have been designed to degrade as a consequence of a change in hydrophobic/hydrophilic 
balance of typically thioester (or sulfide) groups[40-42] or a cleavage of ROS-responsive 
phenylboronic ester groups[43, 44] upon oxidation. Although these advances with single response to 
either esterase or ROS, dual enzyme/oxidation-responsive systems has not been reported yet to our 
best knowledge. 
In this work, we have explored dual enzyme/oxidation-responsive degradation of polyester-based 
nanoparticlulates (DPE-NPs) for tumor-targeting intracellular delivery exhibiting enhanced/controlled 
release of anticancer drugs (Figure 1). Hydrophobic DPE designed with both esterase-responsive ester 
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thiol-ene addition. A facile nanoprecipitation process of DPE with an aid of external polymeric 
stabilizers in water resulted in the fabrication of aqueous core/shell-type DPE NPs loaded with 
anticancer drugs. Polymeric shell composed of poly(ethylene oxide) provides stealth effect to 
minimize immune response and maximize colloidal stability in the blood. Porcine liver esterase and 
hydrogen peroxide were examined to model the response of DPE-NPs to esterase and ROS. Responses 
of DPE-NPs to these stimuli resulted in main chain degradation or polarity change, leading to the 
enhanced release of encapsulated doxorubicin (Dox) or hydrophobic model drug (Nile Red). Further, 
aqueous DPE-NPs were assessed as intracellular nanocarriers in vitro in two-dimensional (2D) 
monolayer cell culture and three-dimensional (3D) multicellular tumor spheroids (MCTS).  
  
Experimental   
Instrumentation. 1H-NMR spectra were recorded using a 500 MHz Varian spectrometer. The 
CDCl3 singlet at 7.26 ppm was selected as the reference standard. Molecular weight and molecular 
weight distribution were determined by gel permeation chromatography (GPC). An Agilent GPC was 
equipped with a 1260 Infinity Isocratic Pump and a RI detector. Two Agilent PLgel mixed-C and 
mixed-D columns were used with DMF containing 0.1 mol% LiBr at 50 °C at a flow rate of 1.0 
mL/min. Linear poly(methyl methacrylate) standards from Fluka were used for calibration. Aliquots of 
the polymer samples were dissolved in DMF/LiBr. The clear solutions were filtered using a 0.45 m 
PTFE filter to remove any solvent-insoluble species. A drop of anisole was added as a flow rate 
marker. The size of DPE-NPs in hydrodynamic diameter was measured by dynamic light scattering 
(DLS) at a fixed scattering angle of 175° at 25 °C with a Malvern Instruments Nano S ZEN1600 
equipped with a 633 nm He-Ne gas laser. Fluorescence spectra on a Varian Cary Eclipse Fluorescence 
spectrometer and UV/Vis spectra on an Agilent Cary 60 UV/Vis spectrometer were recorded using a 1 
cm wide quartz cuvette.  
Transmission Electron Microscopy (TEM) images were obtained using a Philips Tecnai 12 TEM, 
operated at 80kV and equipped with a thermionic LaB6 filament. An AMT V601 DVC camera with 
point to point resolution and line resolution of 0.34 nm and 0.20 nm respectively was used to capture 
images at 2048 by 2048 pixels. To prepare specimens, the NP dispersions were dropped onto copper 
TEM grids (400 mesh, carbon coated), blotted and allowed to air dry at room temperature. 
Subsequently, uranyl acetate (1%) was applied on the TEM grids and then dried again at room 
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Microscope Imaging. Two types of microscopes were used. First, HeLa cells and multi-cellular 
tumor spheroid (HeLa and A549) were visualized with Nikon TI-E microscope equipped with LED 
Heliophors with a Photometrics Evolve EMCCD camera. Secondly, endocytosis mechanism of Dox-
NPs was determined by using inverted Nikon Ti-E Livescan confocal microscope (CLSM) equipped 
with laser source (405 nm and 488 nm), a piezo Z stage (Mad City Labs), iXON897 EMCCD camera 
(Andor). NIS Elements acquisition software was used for both the microscopes. All the images were 
analyzed using Image J (NIH). 
Materials. 2,2’-(ethylenedioxy)diethanethiol (DSH, 95%), ethylene glycol dimethacrylate 
(EGDMA, 98%), triethylamine (Et3N, ≥99%), Brij® S20 (B20), poly(ethylene glycol) (PEG, MW = 
6,000 g/mol), esterase from porcine liver (18 U/mg; one unit will hydrolyze 1 µmol of ethyl butyrate to 
butyric acid and ethanol per minute at pH 8.0 at 25 ºC), Nile Red (NR), doxorubicin hydrochloride 
(Dox, -NH3
+Cl- forms, >98%), hydrogen peroxide (30% w/w), Bovine Serum Albumin (BSA), and 
Immunoglobulin G (IgG) from human serum (≥95%) from Aldrich, Pierce BCA protein assay kit from 
Bio-Rad, dialysis tubing from Spectrum Labs were purchased and used as received. Dulbecco’s 
modified eagle medium (DMEM), F12K medium, and fetal bovine serum (FBS) from Wisent, phenol-
red free DMEM from Thermo Fisher Scientific and 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) from Promega, and Hoescht 33342 from Invitrogen were 
purchased and used for biological assessment in vitro.  
Synthesis of DPE. DSH (3.7 g, 20.2 mmol) was added to a solution consisting of EGDMA (4.0 g, 
20.2 mmol) and Et3N (565 μL, 4.0 mmol) dissolved in DMSO (13.5 mL) to start polymerization. The 
reaction mixture was stirred at room temperature for 24 hrs. The as-synthesized solution was 
precipitated from cold methanol to remove excess Et3N and unreacted monomers. The precipitate was 
isolated by a vacuum filtration and dried in a vacuum oven at room temperature for 12 hrs, prior to 
analysis by 1H NMR in CDCl3 and by GPC. 
Stabilizer-assisted NP formation by solvent evaporation method. An organic solution of the 
purified and dried DPE (10.8 mg) dissolved in THF (2.3 mL) was mixed with an aqueous solution of 
PEG (10.7 mg) and B20 (0.1 mg) in water (13.6 mL). The resulting dispersion was homogenized using 
sonifier (Branson) for 5 min (amplitude = 15 %, 10 sec on, 2.5 sec off) and then kept stirred for 24 hrs 
at room temperature to remove residual THF. A stable NP dispersion was formed at 2.0 mg/mL. The 
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Enzyme/oxidative degradation of NPs. For oxidation-responsive degradation of NPs in the 
presence of hydrogen peroxide, aliquots of aqueous NP dispersion (2.0 mg/mL, 2.3 mL) were 
incubated with 1% v/v hydrogen peroxide under stirring at room temperature. For enzymatic 
degradation in the presence of esterase, aliquots of aqueous NP dispersion (2.0 mg/mL, 1.8 mL) were 
incubated with esterase (1 mg), attaining 10 U. Alternatively, the dispersion was incubated with 
esterase (2 mg) to attain 20 U. DLS was used to follow any changes in size distribution. 
Preparation of Dox-loaded NPs (Dox-NPs). An organic solution containing DPE (12 mg), Dox 
(1 mg), and Et3N (3.5 µL) dissolved in THF (2.8 mL) was mixed with an aqueous solution of B20 (0.6 
mg) and PEG (11.5 mg) in water (11.7 mL). The resulting mixtures were homogenized using a sonifer 
(Branson) for 5 min (amplitude = 15 %, 10 sec on, 2.5 sec off) and stirred for 24 hrs to remove THF. 
They were then dialyzed over water (1 L) for 6 hrs to remove excess (free) Dox and Et3N, yielding 
aqueous Dox-NPs at 2.0 mg/mL. First, the extinction coefficient of Dox was determined in a mixture 
of water/THF (1/4 v/v) using a UV/vis spectroscopy along with Beer-Lambert equation. Then, the 
loading level and loading efficiency of Dox were determined with mixtures consisting of aliquots of 
Dox-NPs (1 mL) mixed with THF (4 mL). The UV/vis spectra were recorded to obtain the absorbance 
at 498 nm. 
Colloidal stability in the presence of proteins. Aqueous DPE NP dispersion (1 mL, 2 mg/mL) 
was divided into two aliquots and was mixed with BSA (1 mL, 80 mg/mL) and IgG (1 mL, 16 mg/mL) 
in PBS. As controls, BSA and IgG solutions were prepared at the same concentrations. The mixtures 
were incubated at 37 C for 48 hrs. Aliquots from each mixture were withdrawn and subjected to 
centrifugation (10,000 rpm x 15 min) to precipitate undesirably-formed aggregates. The supernatants 
were quantitatively analyzed using BCA assays according to the Pierce® BCA assay kit instructions. 
Briefly, supernatant (25 µL) was transferred to a 96-well plate and BCA reagent (200 µL) was added 
to each well. The plate was then placed at 37 C for 30 min and the absorbance was measured at λ = 
562 nm using Powerwave HT Microplate Reader (Bio-Tek). Percentage of free protein was calculated 
by the ratio of the absorbance with NPs to that without NPs (control).  
Esterase-triggered release of Dox from Dox-NPs. An aqueous mixture consisting of an esterase 
stock solution (0.24 mL, 2.6 mg/mL) and a Dox-NP dispersion (0.9 mL, 5.1 mg/mL) in PBS was 
transferred into dialysis tubing (MWCO = 12,000 g/mol) and immersed in PBS (40 mL). The UV 
spectrum of Dox in outer water was recorded at indicated time intervals using a UV/Vis spectrometer. 
For quantitative analysis, Dox (94.8 μg, equivalent to Dox encapsulated in 0.9 mL Dox-NPs) was 
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Degradation of Dox upon oxidation. Dox (0.15 mg) was dissolved in 1% v/v (or 323 mM) 
hydrogen peroxide solution in water (5 mL).  Aliquots taken periodically were analyzed by UV/vis 
spectroscopy to follow the absorbance at 498 nm. 
Oxidation-responsive release of NR from aqueous NR-loaded NPs. First, aqueous NR-loaded 
NPs were prepared as follows; an aqueous stabilizer solution (B20/PEG = 0.05 w/w, 1.1 mg/mL, 10.5 
mL) was mixed with an organic solution consisting of NR (0.9 mg) and DPE (11 mg) in THF (2.4 
mL). The resulting mixture was homogenized for 5 min and stirred for 24 hrs to remove THF, 
followed by filtration using 0.85 μm PES filter (Pall Corporation) to remove free NR. Then, aliquots of 
NR-loaded NPs were mixed with hydrogen peroxide (1% and 5% v/v) while stirring at 37 ºC. Their 
fluorescence spectra (ex = 480 nm) were recorded periodically to follow FL intensity at 620 nm.  
Cell culture. HeLa cervical cancer cells were cultured in DMEM (Dulbecco’s modified Eagle’s 
medium) containing 10% FBS (fetal bovine serum) and 1% antibiotics (50 units/mL penicillin and 50 
units/mL streptomycin) at 37 C in a humidified atmosphere containing 5% CO2. A549 cells were 
cultured in F12K media with same supplemental additives as previously mentioned; 10% FBS and 1% 
antibiotics. 
Cell viability using MTT assay. HeLa cells were plated at 5 x 105 cells per well into a 96-well 
plate and incubated for 24 h in DMEM (100 µL) containing 10 % FBS and 1 % antibiotics. Then, they 
were incubated with various concentrations of empty (Dox-free), free Dox, and Dox-NPs for 48 h. 
Blank controls without nanoparticles (cells only) were run simultaneously as control. Cell viability was 
measured using the CellTiter 96 Non-Radioactive Cell Proliferation Assay kit (MTT, Promega) 
according to the manufacturer’s protocol. Briefly, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) solution (15 µL) was added to each well. After 4 h incubation, the 
medium containing unreacted MTT was carefully removed. DMSO (100 L) was added to each well to 
dissolve the formed formazan purple crystals, and then the absorbance at  = 570 nm was recorded 
using a Powerwave HT Microplate Reader (Bio-Tek). Each concentration was replicated 6 times. Cell 
viability was calculated as the percent ratio of absorbance of mixtures with nanoparticles to control 
(cells only without NPs). 
Live cell imaging. HeLa cells were plated at densities of 1× 105 cells/well in a 4-well glass-
bottom plate (MatTek Corporation) and incubated in media (0.5 mL) at 37 oC for 18 h. The cells were 
stained with Hoechst 33342 dye for 15 min. Then, the cells were washed with PBS three times to 
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Appropriate amounts of free Dox or Dox-NPs were added to attain a final Dox concentration of 2.5 
μg/mL. Imaging was started 10 min post-incubation for 2 hours; images were captured every 10 
minutes. Cells were placed in a chamber (Live Cell Imaging) at 37 ºC with 5% CO2 and imaged using 
an epifluorescence microscope with a 40x/0.95NA objective. Dox and Hoescht 33342 were excited at 
405 nm and at 555 nm, respectively. In another set, HeLa cells were incubated with Dox-NPs 
(encapsulated Dox = 2.5 μg/mL) and free Dox for 12 hrs to examine the intracellular release of Dox 
from Dox-NPs; images were captured after 12 hrs of incubation with the same microscope setting. 
Flow cytometry. HeLa cells were plated at densities of 5×105 cells/well in 6-well dishes and kept 
at 37 C. After 24 h, cells were treated with Dox-NPs (48.6 L, encapsulated Dox = 2.5 g/mL) for 
either 30 min or 12 h. After, the cells were washed with DMEM and treated with trypsin. The cells 
were suspended in DMEM (500 L) for flow cytometry measurements using a FACSCanto II flow 
cytometer (BD Biosciences) and FACSDiva software (BD Biosciences). 
Multi-cellular tumor spheroids. Multi-cellular tumor spheroids (MCTS) were generated from 
HeLa and A549 cells in 96-well plates (BioLite, Thermo Scientific). Wells were coated with 1.5% 
agarose (Biotechnology Grade, BioShop), then seeded with 500-1000 cells in 150 µl of growth 
medium, which were left to aggregate with gravity at 37 °C and 5% CO2. MCTS were grown for 6 to 
10 days, and were monitored daily using an Inverted Invertoskop 40 C light microscope. Once MCTS 
formation was confirmed, they were transferred into 24-well plates coated with agarose in 2 mL of 
growth medium. MCTS were incubated with Dox-NPs (encapsulated Dox = 1.6 μg/mL), free Dox (1.6 
μg/mL) or DPE-NPs (270 μg/mL; control) for 4 days to compare Dox penetration. Images of the 
spheroids were acquired using the epifluorescence microscope with 4x objective; Dox was excited at 
488 nm. Quantitative analysis of the entire surface area of each spheroid was measured and normalized 
to their initial values at time = 0, thereby giving the fluorescence intensity relative to the first values. 
Cellular uptake of Dox-NPs. HeLa cells were plated on 25 mm round coverslips (No. 1.5) at 40-
50% confluency and kept at 37 ºC with 5% CO2 using a heated chamber (Tokai Hit). Cells were pre-
treated for 1 hr with (i) 100 μM Genistein (GEN) to block caveolae-mediated endocytosis, (ii) 
5 μM Chlorpromazine Hydrochloride (CPZ) to block clathrin-dependent receptor-mediated 
endocytosis, or (iii) 100 μM Genistein and 5 μM Chlorpromazine Hydrochloride in combination to 
block both pathways simultaneously. Cell nuclei were stained with Hoechst 33342 dye prior to 
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Cells were imaged for 1 hr before and after treatment with a final concentration of encapsulated 
Dox = 2.5 μg/mL. Live imaging was performed on CLSM using 60x/1.4NA oil immersion objective. 
Dox and Hoescht 33342 were excited at 405 nm and at 488 nm, respectively. The settings were kept 
the same for control cells and each treatment. Z-stacks of 0.5 µm were taken every 5 minutes. 
 
Results and Discussion 
Preparation of DPE and DPE-based NP colloids. A dual enzyme and oxidation-responsive 
polyester (DPE) containing both sulfide and ester linkages on the backbone were synthesized by a 
highly efficient “click” type base-catalyzed thiol-ene polyaddition reaction. The detailed synthesis and 
characterization are described in Supporting Information (Figure S1).  
DPE is hydrophobic, and thus needs external stabilizers to form colloidally-stable NPs in aqueous 
solution. To prepare aqueous NPs, combined stabilizers consisting of PEG and B20 were empolyed. 
PEG is biocompatible and FDA-approved for clinincal use; has low cytotoxicity; provides excellent 
sheath effect; and prevents nonspecific protein adsorption.[45, 46] However, PEG used here has 
relatively high molecular weight with MW = 6,000 g/mol and thus has low ability to reduce the surface 
tension of water due its tendency to hydrophilicity.[47, 48] B20 has a low  molecular weight stabilizer 
consisting of the short chains of hydrophilic PEG (MW = 800 g/mol) and a hydrophobic stearyl 
group.[49] The addition of B20 to the PEG stabilizing system allowed for the synthesis of a 
colloidally-stable DPE NP dispersion. Figure 2a  shows a DLS diagram of the formed colloids in the 
presence of PEG/B20 stabilizers under the conditions of DPE = 0.9 mg/mL, (PEG+B20)/DPE = 1/1, 
and B20/PEG = 5% (by weight) on total stabilizers. The formed NPs had a diameter = 120 ± 1 nm (by 
intensity). TEM analysis indicates the NPs had a diameter = 116 ± 12 nm in dehydrated states.   
  
Enzyme and oxidation-responsive disassembly. Enzyme-responsive disassembly was examined 
as aqueous NPs were mixed with 10 U esterase (Figure 2b). After 7 hrs of incubation with enzyme, 
both DLS diagram and TEM image show the size increase in NPs with multimodal distribution due to 
large aggregation. As control with esterase only in aqueous solution (without NPs), no significant 
change in size distribtion of esterase was observed over 1 day (Figure S2). Similar result showing NP 
size increase is reported for enzyme-degradable hypebranched polyphosphoester micelles.[50] 
Furthermore, the quantitative analysis using a GPC technique to show a decrease in molecular weight 
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these reported results, our result showing the change in size distribution could be attributed to the 
destabilization of colloids upon the enzymatic cleavage of backbone ester linkages in the response to 
the enzymatic reaction.  
Next, oxidation-responsive disassembly was followed with 1% hydrogen peroxide. Different from 
enzymatic reaction, both DLS and TEM images show that the NPs decreased in size with the diameter 
59 nm after 48 hrs of incubation (Figure 2c). Similar result of decrease in NP sizes in response to 
hydrogen peroxide has been reported.[52] Such a change in size distribution could be due to the 
oxidation-response of sulfide linakges to the corresponding sulfoxide and sulfone ones, as described in 
reports where 1H-NMR was used for the quantitiatve analysis of the oxidation of backbone thioether 
groups in the presence of hydrogen peroxide.[53, 54]  
 
Preparation and colloidal stability of Dox-loaded NPs. To assess the use of DPE-NPs as tumor-
targeting intracellular drug delivery nanocarriers, Dox, a clinically-used anticancer drug, was 
encapsulated in the NPs. A mixure consisting of an organic solution of DPE and Dox with an aqueous 
solution of stabilizers was placed in dialysis tubing (MWCO = 12,000 g/mol) and dialyzed against 
water for 6 hrs. This procedure allows for the removal of excess Dox and Et3N, yielding colloidally-
stable aqueous Dox-NPs at a concentration of 2.0 mg/mL. The capacity and efficiency of loading Dox 
in NPs was analyzed. The extinction coefficient of Dox in a mixture of water/THF at 1/4 v/v was 
determined to be 8,700 M-1 cm-1 (see Figure S3 for overlaid UV spectra of Dox and linear progression 
of absorbance at max = 498 nm over various concentrations). An aliquot of aqueous Dox-NPs was 
dissolved in a mixture of water/THF = 1/4 v/v and their UV spectrum were recorded (Figure S4a). 
Using the Beer-Lambert equation with the predetermined extinction coefficient of Dox in water/THF = 
1/4 v/v, the loading level of Dox was 3.6% and encapsulation efficiency was 64%. DLS analysis 
showed that the diameter of loaded NPs was 144 ± 1 nm, which was larger than that of the empty NPs. 
Further, Dox-NPs had a monomodal distribution with no evidence of aggregation (Figure S4b).  
The formed Dox-NPs were evaluated for their shelf-life colloidal stability using DLS. Their 
diameter was unchanged with no precipitation at room temperature over 330 days (Figure S5a). Next, 
they were then examined for non-specific interaction of Dox-NPs with serum (plasma) proteins was 
examined. Serum proteins can form a “protein corona” around NPs, which results in their rapid 
elimination from blood circulation and is highly undesirable.[55, 56] Two of the more abundant 










    
  12 
NPs were incubated with BSA (40 g/L) and IgG (8 g/L) in PBS at pH = 7.2 for 48 hrs. They were 
centrifuged to remove aggregates formed by undesired interactions of NPs with proteins, then the 
supernatants were analyzed using BCA assays to quantify the interaction of NPs with proteins. As 
Figure S5b shows, both BSA and IgG proteins in the supernatants were determined to be >90%. This 
result suggests that these common serum proteins do not cause large aggregation, and thus the NPs 
should have excellent colloidal stability. 
Enhanced release of encapsulated Dox and model drug. The Dox-NPs were examined for their 
ability to release in response to enzyme and oxidation. First, enzyme-responsive enhanced release of 
Dox from Dox-NPs was examined using UV/Vis spectroscopy. An aliquot of Dox-NPs was placed in 
dialysis tubing (MWCO = 12 kDa) and submerged in PBS containing 10 U or 20 U esterase. Similar 
concentrations of esterase were examined for esterase-responsive block copolymer micelles[57] and 
peptide amphiphile-based nanofibers.[58] Aliquots of outer water were taken periodically to record the 
UV/Vis spectra (Figure S6). Then, the absorbance at max = 498 nm was followed to investigate %Dox 
release. As seen in Figure 3, <20% Dox was released from Dox-NPs in the absence of esterase. In the 
presence of esterase, the backbone ester linkages should be targeted, causing destabilization (or 
disintegration) of Dox-NPs to enhance the release of Dox. The released Dox molecules should diffuse 
through the dialysis tubing into outer water and thus the absorbance of Dox in outer water increases. 
Compared with other supramolecular nanostructures,[58] where the change in esterase concentration 
does not have any effect, Dox release occurred in the presence of 10 U esterase, and was faster in the 
presence of 20 U esterase. For example, %Dox reached to as high as 85% with 20 U esterase, 
compared to 60% with 10 U esterase.  
The oxidation-responsive release of Dox from Dox-NPs in response to hydrogen peroxide was 
determined. However, due to the instability of Dox in hydrogen peroxide (1% v/v), the experimental 
approach had to be modified. As seen in our control experiment where Dox was incubated with 1% 
hydrogen peroxide, the absorbance of Dox decreased gradually over the incubation time (Figure S7).  
A hydrophobic model for anti-cancer drugs is Nile Red (NR), which is stable for at least 170 h in 
hydrogen peroxide (5% v/v).[52] Thus, NR-loaded NPs were used as an alternative approach to 
monitor oxidation-responsive release in the presence of hydrogen peroxide using fluorsecence 
spectroscopy. This method can determine changes in the fluorescence intensity of NR in different 
conditions, which would change due to its low solubility in water. NR fluorescence is intense when 
encapsulsted in hydrophobic cores. However, the intensity significantly decreases when NR molecules 
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Here, the solvent evaporation method was used to prepare aqueous NR-loaded NPs (NR-NPs) 
with a diameter = 153 nm (Figure S8). Aliquots were incubated with 1% and 5% hydrogen peroxide 
and their emission spectra were followed over time (Figure S9). In the absence of hydrogen peroxide, 
the fluorescence intensity of NR-NPs at 620 nm remained unchanged, suggesting that NR was not 
released or photobleached. In the presence of hydrogen peroxide, the flourescence intensity decreased 
with kinetics that is correlated with changes in the concentration of hydrogen peroxide (Figure 4a). For 
example, the intensity rapidly decreased to less than 10% within 8 hrs with 5% hydrogen peroxide, 
while it gradually decreased to similar level in 45 hrs. Such a hydrogen peroxide concentration-
dependent release of NR is reported at 0.15-3.3% hydrogen peroxide for self-assembled micelles based 
on a diblock copolymer consisting of poly(propylene sulfide) and poly(N,N-dimethylacrylamide) 
blocks.[52] In addition, the change in hydrophilic/hydrophobic balance upon oxidation is also reported 
at 0.3-1% hydrogen peroxide for polysulfides.[42, 54, 61] 
Interestingly, there was an increase in intensity in 1% hydrogen peroxide. This unusual 
phenomenon could be attributed to self-quenching of NR molecules confined in small-sized NR-loaded 
NPs. Upon destabilization of NR-loaded NPs in response to hydrogen peroxide, NP cores could swell, 
resulting in a decrease in self-quenching of NR molecules. After longer incubation, the fluorescence 
intensity decreased, likely due to further destabilization of NPs.[62, 63] In another analysis, the 
emission wavelength of maximum fluorescence intensity (em,max) was monitored. As seen in Figure 
4b, the em,max increased from 620 nm to 640 nm (max) over the incubation time. This increase in 
wavelength is similar to the decrease in intensity. Given that the em,max of NR is red-shifted when the 
polarity of the medium increases. This increase could arise due to the release of NR molecules from 
NPs upon oxidative degradation.  
Together, these results show the enhanced release of encapsulated drugs (Dox and NR) from DPE- 
NPs in response to both enzymatic activity and oxidation. Nevertheless, further efforts could be made 
to optimize the design of DPE-based NPs targeting the synergistic release profile upon dual stimuli-
responsive degradation at biologically-relevant concentrations of esterase and ROS.  
 
Activity and intracellular uptake in HeLa cells. The cytotoxicity of DPE-NPs was evaluated on 
HeLa cervical cancer cells. Dox-loaded NPs were compared with empty NPs using a MTT 
colorimetric assay. As seen in Figure 5a, HeLa cell viability was >85% in the presence of empty NPs 
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loaded with Dox = 1.7 g/mL (equivalent to 100 g/mL of Dox-NPs), the viability of HeLa cells 
decreased to 44% (Figure 5b). The decreased viability suggests that the proliferation of HeLa cells was 
inhibited by the Dox-NPs. When HeLa cells were treated with the same concentration of free Dox, cell 
viability significantly decreased to <10%, suggesting that free Dox more effectively blocks HeLa cell 
proliferation over 48 hrs, or two doubling times, compared with Dox-NPs.  
Next, the intracellular localization of Dox-NPs was explored using fluorescence microscopy 
(Supplemental movie M1 and M2). Figure 6a shows fluorescence images of HeLa cells 10 min (t = 0) 
and 2 hrs after incubation with free Dox or Dox-NPs. The nuclei were stained with Hoechst 33342, 
shown in blue, and Dox fluorescence is shown in red. Dox fluorescence increased with time in cells 
treated with free Dox or Dox-NPs. However, Dox was seen in the nuclei in cells treated with free Dox, 
while Dox was in the perinuclear region rich in endomembrane networks in cells treated with Dox-
NPs. Therefore, the NPs likely enter cells via endocytosis and traffic to the endomembrane system, 
where their release may be more highly controlled vs. free Dox molecules. Followed by the 
accumulation in the perinuclear region, Dox accumulated in the nuclei post 12 hrs of incubation. This 
is ascribed to the intracellular release of Dox from Dox-NPs (Figure S10). The intracellular 
accumulation of Dox was also monitored using flow cytometry. HeLa cells were analysed using flow 
cytometry after 30 min and 12 hrs of incubation with free Dox or Dox-NPs. As shown in Figure 6b, the 
histogram for free Dox was shifted to higher fluorescence intensity, compared with Dox-NPs after 30 
min of incubation. After 12 hrs, the histogram for Dox-NPs shifted to higher fluorescence intensity 
compared with free Dox (Figure 6c). These changes are more obvious in Figure 6b-e. While there was 
only a slight increase in intensity for free Dox between 30 min and 12 h of incubation, there was a 
significant increase in intensity for Dox-NPs. This result suggests that the internalization of free Dox 
occurs very rapidly, but reaches a threshold with no further internalization. In contrast, the 
internalization of Dox-NPs gradually increases over time with a greater threshold. 
 
Uptake by cells in multicellular tumor spheroids. Multicellular tumor spheroids (hereafter 
referred to as spheroids) grown from cultured cells in vitro have properties that mimic solid tumors in 
vivo, and thus serve as a model to predict the ability of drug-loaded NPs to penetrate tumors.[64] Here, 
HeLa cells were induced to form spheroids and incubated with Dox-NPs or free Dox at 1.6 μg/mL, or 
empty DPE NPs as a control for 4 days. The bright field and fluorescence images of HeLa spheroids in 
Figure 7a show the difference in fluorescence intensity between Dox-NPs and free Dox. Further 
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within 6 hrs; and upon further incubation, the signal steadily increased. After 4 days of incubation, 
spheroids with Dox-NPs had intensities that were five times greater than spheroids with free Dox. 
These results suggest that Dox-NPs are superior in their ability to penetrate accumulate in HeLa 
spheroids compared with free Dox.  Thus, the controlled uptake and increased threshold of Dox-NPs 
could contribute to an overall increased efficacy of uptake at the multicellular level. To determine if 
Dox-NPs can also efficiently penetrate spheroids made from other cell types, a similar experiment was 
performed using spheroids made from A549 lung cancer cells (Figure S11). The uptake of Dox-NPs in 
A549 spheroids was greater than free Dox, suggesting that the NPs enhance uptake with multiple 
cancers. Such enhanced cellular uptake could be the result of the combination of nanoparticle 
characteristics such as size, morphology, and surface charge.  
Endocytic uptake of Dox-NPs in HeLa cells. Polymer-based or inorganic NPs can be 
internalized through several pathways such as clathrin- or caveolae-mediated endocytosis, and 
macropinocytosis.[65-68] As shown in Figure 7, Dox-NPs were visualized in the endomembrane 
system, supporting that they were taken into cells via one of these mechanisms. To gain insight into the 
mechanism of entry for the DPE NPs, HeLa cells were incubated with Dox-NPs after being treated 
without (control) or with chlorpromazine, genistein or a combination of both inhibitors. It has been 
reported that chlorpromazine inhibits clathrin-mediated endocytosis,[69] while genistein inhibits 
caveolae-mediated endocytosis.[70] Thus, blocking the pathway that mediates the uptake of Dox-NPs 
should result in no fluorescence signal inside cells. Figure 8a shows the fluorescence images of HeLa 
cells treated with Dox-NPs for 1 hr. The red color represents the fluorescence Dox signal, while blue 
shows the nuclei. Figure 8b shows the quantitative analysis of Dox fluorescence intensity for each 
treatment normalized to maximum intensity for control (no inhibitors) over 1 hr. While control cells 
reached a maximum of 100% of normalized intensity after 1 hr, this signal was reduced to 50% after 
treatment with chlorpromazine and remained at 0% after genistein treatment, or when treated with both 
inhibitors. These results suggest that caveolae-mediated endocytosis is the dominant pathway for the 
internalization of Dox-NPs into HeLa cells. Furthermore, the results implicate the reason why Dox-
NPs exhibit relatively less cytotoxicity, compared with free Dox, although they had greater cellular 
uptake based on flow cytometry results. Clathrin-mediated endocytosis and macropinocytosis carry 
NPs to lysosomes, which are acidic pH (4.5-5.5) and have degradative enzymes. Under these 
conditions, the NPs could be degraded, resulting in enhanced release of encapsulated Dox. On the 
other hand, caveolae-mediated endocytosis carries caveolar vesicles to caveosomes; thus the release of 
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from NPs could be more beneficial over longer periods time in the context of tumors in vivo, as the 
capacity for their uptake is higher, this could result in a more tightly controlled release of Dox vs. rapid 
accumulation of free Dox at lower levels. 
    
Conclusion   
Dual enzyme/oxidation-responsive DPEs with ester and sulfide linkages on their backbones was 
synthesized by a thiol-ene polyaddition reaction. DPEs were fabricated into aqueous DPE-NP colloids 
with a diameter = 120 nm, which were non-toxic to HeLa cells up to 750 g/mL. They were stable and 
exhibited prolonged colloidal stability when kept for long periods of time on the shelf, or in the 
presence of serum proteins to mimic physiological conditions. The NPs disassembled successfully in 
the presence of esterase and hydrogen peroxide, upon cleavages of the ester linkages and oxidation of 
the sulfide linkages, respectively, as confirmed by DLS analysis. Such dual stimuli-responsive 
degradation enabled the enhanced and controlled release of encapsulated Dox (clinical anticancer drug) 
and NR (fluorescent dye as a model hydrophobic drug) from NPs. Dox-NPs inhibited the proliferation 
of HeLa cells and excitingly, they were internalized with higher thresholds compared to free Dox, 
confirmed by the results from HeLa or A549 cells grown in 2D or 3D spheroids. Further, Dox-NPs 
appeared to enter cells predominantly by caveolae-mediated endocytosis, which would protect them 
from degradation in the lysosomes and permit more controlled release. These results suggest that 
aqueous DPE-NPs hold a potential as an efficient intracellular nanocarrier that can deliver anti-cancer 
therapeutics to inhibit solid tumors.  
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Figure and Scheme captions 
 
Figure 1. Schematic illustration of intracellular drug delivery of DPE-based core/shell NPs loaded 
with Dox.  
Figure 2. DLS diagrams and TEM images (inset) of aqueous DPE NP colloids with an aid of mixed 
PEG/B20 stabilizers in the absence (a) and presence of 10 U esterase (b), and 1 % hydrogen peroxide 
(c) at 0.1 mg/mL and pH = 7.2.  
Figure 3. Release profile in short-term (a) and long-term (b) time scale of Dox from Dox-NPs in the 
absence and presence of 10 U and 20 U esterase at pH = 7.2. Each sample was measured three times. 
Figure 4. Normalized fluorescence (FL) intensity (a) and maximum wavelength of FL intensity (b) of 
NR at λem = 620 nm in the mixture of aqueous NR-loaded NPs incubated with hydrogen peroxide of 
1% and 5%. Each sample was measured three times. 
Figure 5. Viability of HeLa cells incubated with different amounts of empty NPs (a) and Dox-NPs, 
compared with free Dox, (b) for 48 hrs determined by an MTT assay. Data are presented as the average 
± standard deviation (n = 6). 
Figure 6. Time-lapse fluorescence microscopy images of HeLa cells incubated with Dox-NPs 
(encapsulated Dox = 1.6 µg/mL), compared with free Dox (2.5 g/mL), for 2 hrs (a) as well as their 
histograms from flow cytometry after 30 min (b) and 12 hrs (c) of incubation and their comparison of 
free Dox-NPs (d) and Dox (e) over incubation time. Note that the images in red color (Dox) were 
processed differently for free Dox and Dox-NPs due to low signal from free Dox and the high signal 
from Dox-NPs. For all experiments, the amount of Dox-NPs was designed to have the encapsulated 
Dox whose concentration was kept to be 2.5 g/mL. (Scale bar = 30 µm). 
Figure 7. Florescence microscope images of HeLa spheroids incubated for 4 days with Dox NPs 
(encapsulated Dox = 1.6 µg/mL), free Dox (1.6 µg/mL), and empty DPE-NPs (270 µg/mL) as a control 
(a). Quantitative analysis of florescence intensity of the spheroids after short term (24 hrs) (b) and long 
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were processed differently for free Dox and Dox-NPs due to low signal from free Dox and high signal 
from Dox-NPs. (n = 3, scale bar = 200 μm). 
Figure 8. FL images of single cell incubated with Dox-NPs in the absence (control) and presence of 
chlorpromazine (CPZ, inhibiting clathrin-mediated endocytosis), or genistein (GEN, inhibiting 
caveolae-mediated endocytosis), or both inhibitors (a) and quantitative analysis of FL intensity of Dox 
in the perinuclear region normalized with maximum FL intensity of control system (no inhibitors) over 
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Figure 1. Schematic illustration of intracellular drug delivery of DPE-based core/shell NPs loaded 





Figure 2. DLS diagrams and TEM images (inset) of aqueous DPE NP colloids with an aid of mixed 
PEG/B20 stabilizers in the absence (a) and presence of 10 U esterase (b), and 1 % hydrogen peroxide 





1 10 100 1000 10000
Diameter (nm)
1 10 100 1000 10000
Diameter (nm)
Dav = 59 nm
b) c)
1 10 100 1000 10000
Diameter (nm)
a)











    
  24 
 
Figure 3. Release profile in short-term (a) and long-term (b) time scale of Dox from Dox-NPs in the 





Figure 4. Normalized fluorescence (FL) intensity (a) and maximum wavelength of FL intensity (b) of 
NR at λem = 620 nm in the mixture of aqueous NR-loaded NPs incubated with hydrogen peroxide of 
1% and 5%. Each sample was measured three times. 
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Figure 5. Viability of HeLa cells incubated with different amounts of empty NPs (a) and Dox-NPs, 
compared with free Dox, (b) for 48 hrs determined by an MTT assay. Data are presented as the average 




Figure 6. Time-lapse fluorescence microscopy images of HeLa cells incubated with Dox-NPs 
(encapsulated Dox = 1.6 µg/mL), compared with free Dox (2.5 g/mL), for 2 hrs (a) as well as their 
histograms from flow cytometry after 30 min (b) and 12 hrs (c) of incubation and their comparison of 
free Dox-NPs (d) and Dox (e) over incubation time. Note that the images in red color (Dox) were 
processed differently for free Dox and Dox-NPs due to low signal from free Dox and the high signal 
from Dox-NPs. For all experiments, the amount of Dox-NPs was designed to have the encapsulated 
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Figure 7. Florescence microscope images of HeLa spheroids incubated for 4 days with Dox NPs 
(encapsulated Dox = 1.6 µg/mL), free Dox (1.6 µg/mL), and empty DPE-NPs (270 µg/mL) as a control 
(a). Quantitative analysis of florescence intensity of the spheroids after short term (24 hrs) (b) and long 
term (4 days) treatments (c). Each value was normalized by their initial value. *Note that the images 
were processed differently for free Dox and Dox-NPs due to low signal from free Dox and high signal 
from Dox-NPs. (n = 3, scale bar = 200 μm). 
 
  
Figure 8. FL images of single cell incubated with Dox-NPs in the absence (control) and presence of 
chlorpromazine (CPZ, inhibiting clathrin-mediated endocytosis), or genistein (GEN, inhibiting 
caveolae-mediated endocytosis), or both inhibitors (a) and quantitative analysis of FL intensity of Dox 
in the perinuclear region normalized with maximum FL intensity of control system (no inhibitors) over 
1 hr (b) (scale bar = 10 µm) 
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